

Universal Biosensors, Inc.
ABN 51 121 559 993

1 Corporate Avenue
Rowville Victoria 3149
Australia

Telephone: +61 3 9213 9000
Facsimile: +61 3 9213 6490
Email: info@universalbiosensors.com
www.universalbiosensors.com



Universal Biosensors

11 January 2010

Universal Biosensors Inc Board Change

Universal Biosensors, Inc. (ASX: UBI) announced today a change to its board of directors with the appointment of Mr Marshall Heinberg and the retirement of Mr Charles Kiefel.

Mr Heinberg is a well known and respected senior US financial industry executive who serves as Senior Managing Director and Head of Investment & Corporate Banking at Oppenheimer & Co., a leading U.S. based investment bank. Previously, Mr Heinberg was Head of CIBC's U.S. Investment Banking Department.

During his career, Mr. Heinberg has worked with many leading growth companies. Mr. Heinberg has held responsibility for various sectors including environmental, industrial growth, technology and telecommunications. His transaction experience includes public and private financings, exclusive sale and strategic advisory assignments.

"Marshall has extensive experience and insight into the life science industry and the global capital markets," said UBI Chairman, Mr Andrew Denver. "We will benefit from his skills and experience and he is ideally placed to facilitate Universal Biosensors' next phase of growth."

Mr. Heinberg graduated from the University of Pennsylvania, the Wharton School with honours, with a degree in economics, and received his law degree from Fordham Law School.

Whilst welcoming Mr Heinberg, UBI Chairman Andrew Denver also acknowledged the important contribution of the outgoing director Charles Kiefel. "Charles has been a director within the UBI group since 2001. The directors of Universal Biosensors join me in thanking Charles for his counsel and advice over the formative years of the company and his invaluable assistance, particularly his expertise and knowledge of capital markets, as the company developed its first product through the critical phase of obtaining regulatory approval. We wish Charles well in his future endeavours", said UBI chairman Andrew Denver.

Ends

Enquiries:
Mark Morrisson +61 3 9213 9000

About Universal Biosensors

For additional information in relation to Universal Biosensors, refer to
<http://www.universalbiosensors.com/announcements.html>.

Under applicable United States securities laws all of the shares of our common stock are "restricted securities" as that term is defined in Rule 144 under the Securities Act of 1933, as amended (Securities Act). Restricted securities may be resold in the public market to United States persons as defined in Regulation S only if registered for resale or if they qualify for an exemption from registration under the Securities Act. We have not agreed to register any of our common stock for resale by security holders.

Universal Biosensors, Inc.
ABN 51 121 559 993

1 Corporate Avenue
Rowville Victoria 3149
Australia

Telephone: +61 3 9213 9000
Facsimile: +61 3 9213 6490
Email: info@universalbiosensors.com
www.universalbiosensors.com



Universal Biosensors

Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of *in vitro* diagnostic tests for point-of-care use. These tests capitalize on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

Universal Biosensors' first product, developed in conjunction with LifeScan, Inc, is a next generation test for diabetics to self – monitor blood glucose. The product received its first clearance to sell in November 2009 and is expected to appear in market in 2010. The relationship with LifeScan, Inc dates from 2001. In 2009 the two companies entered an updated Master Services and Supply Agreement under which Universal Biosensors agreed to be a non-exclusive manufacturer of blood glucose sensor strips for the product that is about to come to market. Universal Biosensors CEO Mark Morrisson has previously estimated that there are approximately 16 billion glucose sensor strips sold worldwide into a market in which LifeScan is a major participant.

Universal Biosensors is currently developing other point-of-care blood tests from its technology platform, which it intends to partner in due course.

Under applicable United States securities laws all of the shares of our common stock are “restricted securities” as that term is defined in Rule 144 under the Securities Act of 1933, as amended (Securities Act). Restricted securities may be resold in the public market to United States persons as defined in Regulation S only if registered for resale or if they qualify for an exemption from registration under the Securities Act. We have not agreed to register any of our common stock for resale by security holders.